CLONIDINE TO PREVENT IMPLANTABLE CARDIOVERTER DEFIBRILLATOR FIRING

可乐定可防止植入式心脏复律除颤器起火

• 批准号: 7604906
• 负责人: James B Martins
• 金额: $ 0.04万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604906
• 关键词: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Cardiac; Clonidine; Computer Retrieval of Information on Scientific Projects Database; Data; Devices; Drug Prescriptions; End Point; Fire - disasters; Funding; Grant; Heart Arrest; Heart Diseases; Implantable Defibrillators; Informed Consent; Institution; Invasive; Metoprolol; Patients; Pharmaceutical Preparations; Purpose; Randomized; Research; Research Personnel; Resources; Shock; Source; Testing; Time; United States National Institutes of Health; Ventricular Tachycardia; base; blind; day; improved; outcome forecast; prevent; programs

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cardiac arrest or sustained ventricular tachycardia (VT) in patients with heart disease is best treated with an implantable cardioverter defibrillator (ICD). However, the ICD alone is not appropriate therapy for patients with frequent VT episodes. In fact, frequent shocks for VT may predict a poorer prognosis. Antiarrhythmic drugs are co-administered with ICDs in up to 50% of patients to prevent VT episodes, but antiarrhythmic drugs may have harmful effects. Thus, improved drugs to prevent VT without interfering with ICD function are needed. Recent data suggest that clonidine may be a new therapy to prevent ICD shocks. It may act centrally on sympathetic outflow and peripherally and selectively on cardiac Purkinje to suppress and control VT occurring in patients. The purpose of this study is to test the hypothesis that clonidine reduces frequent VT better than beta blocker in patients with ICDs. After informed consent, patients will be randomized in a single blind fashion to either clonidine or metoprolol given three times per day. Other prescribed drugs may be adjusted to promote toleration of the study drug. ICD interrogrations of episodes of VT will be the primary endpoint. Device based non-invasive programmed stimulation (NIPS) testing in a subset of these patients will allow mechanistic understanding of the clonidine effect.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 心脏病患者的心脏骤停或持续性室性心动过速(VT)最好使用植入型心律转复除颤器(ICD)进行治疗。然而，对于室速发作频繁的患者来说，ICD本身并不是合适的治疗方法。事实上，室性心动过速频繁的电击可能预示较差的预后。在高达50%的患者中，抗心律失常药物与ICD联合使用以防止VT发作，但抗心律失常药物可能会产生有害影响。因此，需要改进药物在不干扰ICD功能的情况下预防室性心动过速。最近的数据表明，可乐定可能是预防ICD休克的一种新疗法。它可中枢作用于交感神经流出，外周选择性作用于心脏浦肯野，抑制和控制患者发生的室性心动过速。本研究的目的是验证可乐定比β受体阻滞剂更好地降低ICD患者频发室性心动过速的假设。在知情同意后，患者将以单盲方式随机给予可乐定或美托洛尔，每天三次。其他处方药可能会进行调整，以促进研究药物的耐受性。对室性心动过速发作的ICD询问将是主要终点。在这些患者中的一部分患者中进行基于设备的非侵入性程序刺激(NIPS)测试将允许从机制上理解可乐定效应。